This paper studies the incentives that developing countries have to protect intellectual properties rights (IPR). On the one hand, free-riding on rich countries technology reduces their investment cost in R&D. On the other hand, firm that violates IPR cannot legally export in a country that...

This paper analyses the causal impact of Intellectual Property Rights (IPR) on pharmaceutical innovation in a panel of 74 countries. The identification strategy exploits the different timing across countries of two sets of IPR reforms. Domestic innovation is measured as citation-weighted...

The paper addresses the question of whether expanded and strengthened protection of intellectual property (IP) fosters technology transfer to developing countries. Cross-sectional analysis of a representative sample of firms operating in 42 developing economies indicates that going from no IP...

This WTO working paper studies availability and affordability of new and innovative pharmaceuticals in a post-TRIPS era. The WTO's TRIPS Agreement (TRIPS) makes it obligatory for WTO members − except least-developed country members (LDCs) - to provide pharmaceutical product patents with a...